05.23.18
mAbxience, a company specialized in the research, development, manufacturing and global commercialization of monoclonal antibody biosimilars, part of the Insud Pharma Group, and Amneal Pharmaceuticals, an integrated specialty pharmaceutical company powered by a robust U.S. generics business, have signed an exclusive licensing and supply agreement in the U.S. for mAbxience's bevacizumab, a biosimilar candidate for Avastin.
Under the milestone based commercial agreement mAbxience will lead product, clinical development and subsequent manufacture while Amneal will guide the product through regulatory approval and have exclusive commercialization rights in the U.S.
"We are very proud to deepen our partnership with Amneal with the bevacizumab biosimilar agreement. We are passionate about increasing access and affordability of biologics in all countries around the world and this latest agreement with Amneal will be an important contribution to public health in the United States," said Emmanuelle Lepine, general manager, mAbxience.
mAbxience is progressing its international expansion, and recently established partnerships in Europe and Australia for its bevacizumab biosimilar.
Under the milestone based commercial agreement mAbxience will lead product, clinical development and subsequent manufacture while Amneal will guide the product through regulatory approval and have exclusive commercialization rights in the U.S.
"We are very proud to deepen our partnership with Amneal with the bevacizumab biosimilar agreement. We are passionate about increasing access and affordability of biologics in all countries around the world and this latest agreement with Amneal will be an important contribution to public health in the United States," said Emmanuelle Lepine, general manager, mAbxience.
mAbxience is progressing its international expansion, and recently established partnerships in Europe and Australia for its bevacizumab biosimilar.
